RxDoctor Payments Data

Thomas Stoughton, MD

Cardiovascular Disease · Florence, SCNPI 1316905144

Payments from drug & device makers

$1,021in general payments, 2019–2025

Across 28 payments — averaging $36.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inari Medical, Inc.$181
  • Abbott$150
  • Novartis$123
  • Boston Scientific$114
  • Medtronic$103
  • Amgen$97
  • plus $253 from 9 others

What the payments were for

  • Food & beverage$1,00799%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,021 in reported general payments places this provider in the 20th percentile of 257 cardiovascular disease providers in South Carolina.

See all cardiovascular disease providers in South Carolina

Medicare billing

Part B allowed, 2024
$243,205
Medicare patients
2,781
Services billed
5,821

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban221$233,104
JardianceEmpagliflozin125$117,199
EntrestoSacubitril/Valsartan72$105,523
XareltoRivaroxaban30$42,682
Repatha SureclickEvolocumab31$29,532
MultaqDronedarone Hcl25$22,934
FarxigaDapagliflozin Propanediol13$17,308
BrilintaTicagrelor29$17,174
CorlanorIvabradine Hcl19$11,140
Ranolazine ErRanolazine139$9,939
Metoprolol Succinate360$4,203
Carvedilol434$3,769
Atorvastatin Calcium266$3,712
Dofetilide25$3,042
ClopidogrelClopidogrel Bisulfate201$2,616

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$15$233,104221 claims
NovartisEntresto$123$105,52372 claims
Johnson & JohnsonXarelto$14$42,68230 claims
AstraZenecaFarxiga, Brilinta$14$34,48242 claims
AmgenCorlanor$97$11,14019 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 257 cardiovascular disease providers in South Carolina.

Other cardiovascular disease in Florence

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →